Summit Therapeutics PLC (SMMT)
NASDAQ:SMMT
Want to see SMMT full AI Analyst Report?
Total Valuation
Summit Therapeutics has a market cap or net worth of $12.90B. The enterprise value is $12.82B.
Market Cap$12.90B
Enterprise Value$12.82B
Share Statistics
Summit Therapeutics has 776,162,660 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding776,162,660
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Summit Therapeutics’s return on equity (ROE) is -2.21 and return on invested capital (ROIC) is -216.35%.
Return on Equity (ROE)-2.21
Return on Assets (ROA)-1.94
Return on Invested Capital (ROIC)-216.35%
Return on Capital Employed (ROCE)-2.17
Revenue Per Employee0.00
Profits Per Employee-5.04M
Employee Count159
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Summit Therapeutics is ―. Summit Therapeutics’s PEG ratio is -0.03.
PE Ratio―
PS Ratio0.00
PB Ratio26.74
Price to Fair Value26.74
Price to FCF-54.45
Price to Operating Cash Flow-44.98
PEG Ratio-0.03
Income Statement
In the last 12 months, Summit Therapeutics had revenue of 0.00 and earned -1.08B in profits. Earnings per share was -1.44.
Revenue0.00
Gross Profit0.00
Operating Income-1.09B
Pretax Income-1.08B
Net Income-1.08B
EBITDA-1.08B
Earnings Per Share (EPS)-1.44
Cash Flow
In the last 12 months, operating cash flow was -286.56M and capital expenditures -360.29K, giving a free cash flow of -286.92M billion.
Operating Cash Flow-286.56M
Free Cash Flow-286.92M
Free Cash Flow per Share-0.37
Dividends & Yields
Summit Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.68
52-Week Price Change-35.18%
50-Day Moving Average18.89
200-Day Moving Average18.97
Relative Strength Index (RSI)41.98
Average Volume (3m)4.71M
Important Dates
Summit Therapeutics upcoming earnings date is Aug 12, 2026, After Close (Confirmed).
Last Earnings DateApr 30, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Summit Therapeutics as a current ratio of 9.87, with Debt / Equity ratio of 3.67%
Current Ratio9.87
Quick Ratio9.87
Debt to Market Cap0.00
Net Debt to EBITDA0.14
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Summit Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Summit Therapeutics EV to EBITDA ratio is -11.97, with an EV/FCF ratio of -53.82.
EV to Sales0.00
EV to EBITDA-11.97
EV to Free Cash Flow-53.82
EV to Operating Cash Flow-53.93
Balance Sheet
Summit Therapeutics has $454.05M in cash and marketable securities with $15.20M in debt, giving a net cash position of $438.86M billion.
Cash & Marketable Securities$454.05M
Total Debt$15.20M
Net Cash$438.86M
Net Cash Per Share$0.57
Tangible Book Value Per Share$0.65
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Summit Therapeutics is $29.56, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$29.56
Price Target Upside17.53% Upside
Analyst ConsensusModerate Buy
Analyst Count14
Revenue Growth Forecast―
EPS Growth Forecast-384.68%